 After the safety of fibrinogen concentrate FIB Grifols is assessed in at least 10 adult subjects and no safety issues are raised by the sponsor, the study will start to enroll approximately 10 pediatric subjects who will be dosed with study drug and followed for PK, efficacy, and safety assessments. 